Abstract
Pancreatic ribonuclease A (RNase A) has been shown to aggregate moderately and gradually at 65°C. Antibodies raised against the dodecapeptide KETAAAKFERQG corresponding to the N-terminal 1-12 amino acid residues of RNase A (Npep) as well as native RNase A were effective in lowering RNase A aggregation at 65°C. The antiRNase A antibodies were, however, more protective. The binding of antiNpep antibodies to the N-terminal region of RNase A may interfere with initiation of oligomerization of the enzyme and consequently its aggregation. The antiRNase A antibodies were presumably more effective in protecting RNase A against aggregation by binding to multiple epitopes of the enzyme including the N-terminal region and hence restricting the interaction of the monomers.
Keywords: ribonuclease A, antibodies, aggregation inhibition
Protein & Peptide Letters
Title: Inhibition of Pancreatic Ribonuclease A Aggregation by Antibodies Raised Against the Native Enzyme and Its N-Terminal Dodecapeptide
Volume: 13 Issue: 7
Author(s): Hina Younus, Renate Ulbrich-Hofmann and Mohammad Saleemuddin
Affiliation:
Keywords: ribonuclease A, antibodies, aggregation inhibition
Abstract: Pancreatic ribonuclease A (RNase A) has been shown to aggregate moderately and gradually at 65°C. Antibodies raised against the dodecapeptide KETAAAKFERQG corresponding to the N-terminal 1-12 amino acid residues of RNase A (Npep) as well as native RNase A were effective in lowering RNase A aggregation at 65°C. The antiRNase A antibodies were, however, more protective. The binding of antiNpep antibodies to the N-terminal region of RNase A may interfere with initiation of oligomerization of the enzyme and consequently its aggregation. The antiRNase A antibodies were presumably more effective in protecting RNase A against aggregation by binding to multiple epitopes of the enzyme including the N-terminal region and hence restricting the interaction of the monomers.
Export Options
About this article
Cite this article as:
Younus Hina, Ulbrich-Hofmann Renate and Saleemuddin Mohammad, Inhibition of Pancreatic Ribonuclease A Aggregation by Antibodies Raised Against the Native Enzyme and Its N-Terminal Dodecapeptide, Protein & Peptide Letters 2006; 13 (7) . https://dx.doi.org/10.2174/092986606777790629
DOI https://dx.doi.org/10.2174/092986606777790629 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry The Physiology of Learning and Memory: Role of Peptides and Stress
Current Protein & Peptide Science Natural Sirtuin Modulators in Drug Discovery: A Review (2010 -2020)
Current Medicinal Chemistry Current Perspectives on Cytokines for Anti-retroviral Therapy in AIDS Related B-cell Lymphomas
Current Drug Targets - Infectious Disorders Influence of Adrenalectomy on Protective Effects of Urocortin I, a Corticotropin-Releasing Factor, Against Indomethacin-Induced Enteropathy in Rats
Current Neuropharmacology Plant Extracts as a Natural Source of Bioactive Compounds and Potential Remedy for the Treatment of Certain Skin Diseases
Current Pharmaceutical Design Towards Next Generation Adenosine A<sub>2A</sub> Receptor Antagonists
Current Medicinal Chemistry The Endocrine Regulation of Stem Cells: Physiological Importance and Pharmacological Potentials for Cell-Based Therapy
Current Stem Cell Research & Therapy The Expression of Relaxin-3 in Adipose Tissue and its Effects on Adipogenesis
Protein & Peptide Letters Inulin as a Delivery Vehicle for Targeting Colon-Specific Cancer
Current Drug Delivery Editorial (Thematic Issue: New Therapeutic Targets for Autism Spectrum Disorders)
CNS & Neurological Disorders - Drug Targets Alveolar Bone Mineral Density Measurement using CBCT Images
Neuroscience and Biomedical Engineering (Discontinued) Destroying RNA as a Therapeutic Approach
Current Medicinal Chemistry Astrocytes as a 5-HT2B-Mediated SERT-Independent SSRI Target, Slowly Altering Depression-Associated Genes and Function
Current Signal Transduction Therapy Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Exposure of Aggregation-Prone Segments is the Requirement for Amyloid Fibril Formation
Current Protein & Peptide Science Editorial (Thematic Issue: Current Update on Association Between Alzheimer’s Disease and Type 2 Diabetes: Volume I)
CNS & Neurological Disorders - Drug Targets Viruses in Semen and Male Genital Tissues - Consequences for the Reproductive System and Therapeutic Perspectives
Current Pharmaceutical Design AT1 Receptor Antagonists
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Current Status of Drug Delivery Approaches and Assay of Anti-Migraine Drugs
Current Drug Delivery